Alongside the liver, white adipose tissue (WAT) is critical in regulating systemic energy
homeostasis. Although each organ has its specialised functions, they must work …

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

The pathogenesis of non-alcoholic fatty liver disease, particularly the mechanisms whereby
a minority of patients develop a more severe phenotype characterised by hepatocellular …

Summary Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis,
concentrations of liver enzymes, and insulin resistance in murine models of fatty liver …

Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …

Background The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing
worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver …

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

Background The prevalence of non-alcoholic fatty liver disease (NAFLD) has been
increasing rapidly. It is nowadays recognized as the most frequent liver disease, affecting a …

Lifestyle modifications focused on healthy eating and regular exercise are the primary
recommendations for patients with nonalcoholic steatohepatitis (NASH). However, for …